The Myelodysplastic Syndromes Channel is supported with funding from Geron (Silver).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
MDS 2023 | The impact of disease heterogeneity on treatment decisions in MDS
Eric Solary, MD, Gustave Roussy Institute, Paris, France, comments on the heterogeneity of myelodysplastic syndromes (MDS) in terms of both disease staging and molecular mechanisms, highlighting how disease heterogeneity influences treatment decisions. This interview was recorded at the 17th International Congress on Myelodysplastic Syndromes (MDS) 2023, held in Marseille, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
